Mallinckrodt PLC is a global specialty pharmaceutical company that develops, manufactures, markets, and distributes a range of therapeutic products. The company focuses on addressing autoimmune and rare diseases, with expertise in areas such as neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Its product portfolio includes immunotherapy and neonatal respiratory therapies, analgesics, and gastrointestinal products. Mallinckrodt operates through two primary segments: Specialty Brands, which encompasses its proprietary pharmaceutical brands, and Specialty Generics, which includes niche generic drugs and active pharmaceutical ingredients. The majority of the company's revenue is derived from the Specialty Brands segment. With strong capabilities in the management of regulated raw materials, regulatory knowledge, and manufacturing logistics, Mallinckrodt is well-positioned to navigate the complexities of the pharmaceutical industry and meet the needs of patients globally.
Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.
Sucampo Pharmaceuticals, Inc. is engaged in the development and commercialization of specialized medicines targeting significant unmet medical needs globally. The company markets two primary products: AMITIZA, which addresses various forms of constipation, and RESCULA. Sucampo's pipeline includes VTS-270, a treatment for Niemann-Pick Disease Type C-1 currently undergoing a pivotal Phase 2/3 clinical trial. This drug has received orphan designation in both the U.S. and Europe. Additionally, Sucampo holds an option for the North American rights to CPP1-x/sulindac, which is in Phase 3 development for familial adenomatous polyposis and has also been granted orphan drug designation in the U.S. Headquartered in Rockville, Maryland, Sucampo operates internationally with facilities in Japan and Switzerland.
Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute and chronic liver diseases, addressing significant unmet medical needs. The company's lead product, OCR-002, is an ammonia scavenger available in both intravenous and oral formulations, specifically targeting hyperammonemia. Ocera recently completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. The company is planning to engage with the FDA to explore potential development pathways for its intravenous program later this year.
InfaCare Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing treatments for neonatal and pediatric patients. Founded in 2005 and headquartered in Trevose, Pennsylvania, the company is advancing its lead product, Stanate, which is designed to treat infantile jaundice, also known as hyperbilirubinemia. Stanate is a heme oxygenase inhibitor administered via a single intramuscular injection, targeting the breakdown of heme and inhibiting bilirubin production in both term and preterm newborns. This innovative approach aims to reduce the necessity for common interventions such as phototherapy and exchange transfusions, thereby improving care for vulnerable infant populations.
Stratatech Corporation is a regenerative medicine company focused on developing and commercializing cell-based and tissue-engineered skin substitute products for therapeutic and research purposes. Based in Madison, Wisconsin, the company specializes in human tissue substitutes created from NIKS keratinocytes and their derived cells. Its notable products include StrataGraft, a temporary wound cover that enhances healing by utilizing the patient's own cells, and ExpressGraft, a genetically enhanced skin tissue designed to produce natural wound healing and antimicrobial factors. Founded in 2000, Stratatech aims to provide effective solutions for chronic and non-healing wounds, facilitating improved patient care and outcomes.
Therakos, Inc. is a healthcare company that specializes in immunotherapy, specifically focusing on extracorporeal photopheresis (ECP) for the treatment of skin manifestations of Cutaneous T-cell Lymphoma (CTCL) that do not respond to conventional therapies. The company's primary product, the CELLEX System, integrates cell collection, photoactivation, and reinfusion technologies into a single, closed system, which minimizes the risks of infection and patient reinfusion errors. This innovative platform allows for single-operator management of the photopheresis process, enhancing safety and efficiency. Therakos serves a range of healthcare settings, including academic medical centers and hospitals, both in the United States and internationally. Incorporated in 1984 and based in West Chester, Pennsylvania, Therakos operates as a subsidiary of Mallinckrodt Public Limited Company.
Ikaria is an integrated critical care company dedicated to developing and delivering innovative therapeutics and interventions for critically ill patients. The company focuses on creating advanced therapies that address the unique and complex medical needs of these patients. By providing essential support to clinicians, Ikaria aims to enhance patient care at critical moments, positioning itself as a vital partner in the healthcare ecosystem.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our specific areas of focus are in the fields of neurology and nephrology and we are currently supporting research efforts in a variety of conditions having significant unmet medical need.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.
CNS Therapeutics, located in St. Paul, Minnesota, is a private company focused on developing and marketing pharmaceuticals designed for targeted delivery to the central nervous system. The company aims to address neurological disorders and chronic pain through innovative treatments. Its first product, Gablofen, has received FDA approval and is used for intrathecal baclofen therapy. CNS Therapeutics is also engaged in collaborations with both U.S. and international experts to create and evaluate new therapeutic options for conditions such as pain and Parkinson's disease.
Nellcor Puritan Bennett
Acquisition in 1997
Nellcor Puritan Bennett manufactures patient monitoring instruments and disposable supplies for use in surgery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.